Ligand-dependent reprogramming of HNF4A expression and function suppresses multistep hepatocarcinogenesis
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201246
DOI: 10.1016/j.omton.2026.201246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Hikari Okada und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa 920-8641, Ishikawa, Japan. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Kowa Company.
Abstract (Originalsprache)
Activation of tumor suppressors represents an attractive strategy for cancer treatment. Hepatocyte nuclear factor 4 alpha (HNF4A) functions as a tumor suppressor in the liver by inhibiting hepatocyte proliferation; however, no effective agonists have been identified. Here, we aimed to identify novel ligands for HNF4A and evaluate their role in hepatocarcinogenesis. We identified polyprenoic acid (PA, peretinoin) as the first ligand capable of directly binding HNF4A. Reanalysis of prior clinical trial data revealed that PA suppressed the progression of dysplastic nodules (DNs) to hepatocellular carcinoma (HCC), while showing no effect on local HCC recurrence after initial treatment. Consistently, PA inhibited DN growth but not established HCC in Pdgf-C transgenic mice. Mechanistically, PA selectively bound to the HNF4A P1 isoform, enhancing its transcriptional activity and upregulating hepatocyte maturation markers (ALB, TTR, and SLCO1B3), while suppressing alpha-fetoprotein expression driven by the HNF4A P2 isoform. Importantly, hepatocyte-specific Hnf4a knockdown or lipid-nanoparticle-mediated Hnf4a siRNA abrogated the protective effects of PA. These findings establish HNF4A as a pharmacologically controllable tumor suppressor and highlight PA-like compounds as promising agents for preventing liver carcinogenesis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa 920-8641, Ishikawa, Japan.
- Department of Information-Based Medicine Development, Kanazawa University Graduate School of Medical Sciences, Kanazawa 920-8641, Ishikawa, Japan.
- Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-0942, Ishikawa, Japan.
- Faculty of Pharmacy, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Ishikawa, Japan.
- Molecular Profiling Research Center for Drug Discovery (molprof), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo 135-0064, Japan.
- Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Tsukuba Ibaraki 305-8575, Japan.
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Kowa Company
Zitieren
APA
Okada, H., Nio, K., Ohno, N., Masuo, Y., Hirokawa, T., Shimakami, T., Miyati, T., Takamura, H., Ohta, T., Kitao, A., Kobayashi, S., Gabata, T., Matsui, O., Kato, Y., Seiki, M., Honda, M., Kaneko, S., & Yamashita, T. (2026). Ligand-dependent reprogramming of HNF4A expression and function suppresses multistep hepatocarcinogenesis. Molecular Therapy Oncology, 34(2), 201246. https://doi.org/10.1016/j.omton.2026.201246
Vancouver
Okada H, Nio K, Ohno N, Masuo Y, Hirokawa T, Shimakami T, et al. Ligand-dependent reprogramming of HNF4A expression and function suppresses multistep hepatocarcinogenesis. Molecular Therapy Oncology. 2026;34(2):201246. doi:10.1016/j.omton.2026.201246
BibTeX
@article{Okada2026,
author = {Okada, Hikari and Nio, Kouki and Ohno, Naoki and Masuo, Yusuke and Hirokawa, Takatsugu and Shimakami, Tetsuro and Miyati, Tosiaki and Takamura, Hiroyuki and Ohta, Tetsuo and Kitao, Azusa and Kobayashi, Satoshi and Gabata, Toshifumi and Matsui, Osamu and Kato, Yukio and Seiki, Motoharu and Honda, Masao and Kaneko, Shuichi and Yamashita, Taro},
title = {Ligand-dependent reprogramming of HNF4A expression and function suppresses multistep hepatocarcinogenesis},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201246},
doi = {10.1016/j.omton.2026.201246}
}
EUVIMED